Memorial Sloan Kettering Cancer Center

Antitumor Assessment

ABOUT US

Our mission, vision & core values

Leadership

History

Equality, diversity & inclusion

Annual report

Give to MSK

Elisa de Stanchina
Director

The Antitumor Assessment Core Facility was established in 2003 to provide highly qualified services to foster cancer research and to support early discovery of effective antitumor agents and regimens of therapies at Memorial Sloan Kettering Cancer Center. In particular, the facility provides resources, professional and technical expertise, and advisory services related to the evaluation of agents with potential therapeutic activity. The facility works closely with investigators to establish in vivo mouse models; design and execute pharmacokinetic, toxicity, and in vivo efficacy studies; and determine the best

formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents.

View More →

VIDEO | 04:00

Learn more about the resources and state-of-the-art technology that are available within MSK's core facilities.

Video Details →

‹ ›

Featured News



Memorial Sloan Kettering Cancer Center Tops Prestigious List of Highly Cited Researchers 2022

Tuesday, November 15, 2022

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that it is ranked among the top 15 organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers published by the Institute for Scientific Information at Clarivate.

A Closer Look at Breakthroughs in Medicine for Brain Metastasis

MSK medical oncologist Bob Li discusses new opportunities in brain metastasis care thanks to innovative technology and medical breakthroughs.

Growing Science: A Decade Devoted to Advancing Cancer Research at the Sloan Kettering Institute

Saturday, January 1, 2011

A decade ago, the Sloan Kettering Institute embarked on an effort to broaden and streamline its

research activities.

Publications

Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, Ciampricotti M, Qeriqi B, Bahr A, de Stanchina E, Bhanot UK, Lai WV, Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen T, Mazutis L, Hollmann TJ, Pe'er D, Rudin CM. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021 Nov 8;39(11)

Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, Zamarin D, Shi H, Budhu S, Wohlhieter C, Uddin F, Gupta A, Khodos I, Waninger JJ, Qin A, Markowitz GJ, Mittal V, Balachandran V, Durham JN, Le DT, Zou W, Shah SP, McPherson A, Panageas K, Lewis JS, Perry JSA, de Stanchina E, Sen T, Poirier JT, Wolchok JD, Rudin CM, Merghoub T. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. Cancer Cell. 2021 Jul 12;39(7)

Ruscetti M, Morris JP 4th, Mezzadra R, Russell J, Leibold J, Romesser PB, Simon J, Kulick A, Ho YJ, Fennell M, Li J, Norgard RJ, Wilkinson JE, Alonso-Curbelo D, Sridharan R, Heller DA, de Stanchina E, Stanger BZ, Sherr CJ, Lowe SW. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell. 2020 Apr 16;181(2):424-441.e21. Epub 2020 Mar 31. Erratum in: Cell. 2021 Sep 2;184(18)

Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, Da Cruz Paula AF, Saiki AY, Mohn D, Achanta P, Sisk AE, Arora KS, Roy RS, Kim D, Li C, Lim LP, Li M, Bahr A, Loomis BR, de Stanchina E, Reis-Filho JS, Weigelt B, Berger M, Riely G, Arbour KC, Lipford JR, Li BT, Lito P. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021 Nov;599(7886)

Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020 Aug 10;38(2)

View All Publications

People

Elisa de Stanchina

Director

Members





Juan (Jane) Qiu

Senior Research Assistant

Huiyong Zhao

Senior Research Assistant

Michael Kaufmann

Clinical Research Coordinator

Phoebe Bacchus

Research Technician

Cody Bisram

Software Engineer I

Sydney Bowker

Research Technician



Hong Yi Cai

Research Technician

Qing Chang

Scientific Research Lead

Kevin Chen

Research Technician

Xiaoping Chen

Senior Research Assistant



Ana Crawford

Lead Assistant

Idollia Gunpot

Research Technician

Inna Khodos

Senior Research Assistant



Amanda Kulick

Senior Research Assistant

Charlene Kwong

Clinical Research Specialist

Jeanine Lisanti

Clinical Research Coordinator

Vladimir (Vladi) Markov

Research Technician

Maximiliano (Max) Meneses

Research Project Associate

Surabhi Parte

Research Technician



Besnik Qeriqi

Senior Research Assistant



Christie Shea

Senior Research Technician

Vanessa Thompson

GLP Manager

Akiba Waterman
Research Technician

Yu (Yuxin) Zhu
Research Technician

Get in Touch

destance@mskcc.org
Director Email

646-888-2142/2160 (Pager: #5735)
Office Phone